November 12, 2014
Notes: Petrov, Max
ISRN Inflamm. 2013 Dec 29;2013:341410. doi: 10.1155/2013/341410. eCollection 2013.
Author Address: Department of Surgery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Reference Type: Journal Article
Record Number: 4747Author: Petrushenko, V. V., Sukhodolia, S. A., Falalieieva, T. M. and Berehova, T. V.
Title: [New approach for treatment of chronic pancreatitis, caused by L-arginine, in rats]
Journal: Klin Khir
Short Title: [New approach for treatment of chronic pancreatitis, caused by L-arginine, in rats]
Alternate Journal: Klinichna khirurhiia / Ministerstvo okhorony zdorov’ia Ukrainy, Naukove tovarystvo khirurhiv Ukrainy
ISSN: 0023-2130 (Print)
Accession Number: 24502017
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
Cyclooxygenase 2 Inhibitors/*pharmacology
Fibrosis/*prevention & control
Pancreatitis, Chronic/blood/chemically induced/*drug therapy/pathology
Abstract: Impact of rofecoxib on progressing of pancreatic fibrous changes in the rats in experimental chronic pancreatitis, caused by L-arginine, was studied up. In 60 male rats chronic pancreatitis was simulated, using intraabdominal L-arginine introduction (100 mg/100 g) through 21 days. Rofecoxib (5 mg/kg) was injected during 14 days to rats of the main group after L-arginine injections were completed. In 35 days of experiment the animals state, the pancreatic amylase and lipase activity in the blood serum, as well as morphological changes in pancreatic gland, were analyzed. Application of rofecoxib have had promoted the postponed pancreatic fibrosis formation, the morphofunctional state of pancreatic gland improvement. The data obtained constitute the experimental substantiation of possibility to apply nonsteroid antiinflammatory medicines in complex of clinical treatment of chronic pancreatitis.